Company / Profit Margin
Inmune Bio, Inc. Profit Margin History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-300585.7%
FY2025
5-year range
-300585.7% / -7299.2%
FY2021-FY2025
Trend
-1452.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin changed -1453% YoY in FY2025, a notable deviation from the 5-year average annual change of -307%.
Based on SEC 10-K filings.
-300585.7% in FY2025 with a 5-year CAGR of -230245.7%.
Declined from -7299.2% to -300585.7% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- -283823.3pp
- 5-Year Change
- -230245.7pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, profit margin decreased 1452.6% year-over-year.
- Peak profit margin was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -300585.7% | -1452.6% |
| FY2024 | -19360.0% | -165.2% |
| FY2023 | -7299.2% | +56.5% |
| FY2022 | -16762.4% | +84.8% |
| FY2021 | -109990.9% | -56.4% |
| FY2020 | -70340.0% | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026